Abstract
BackgroundBecause alcohol use disorders (AUDs) in patients living with HIV/AIDS are associated with a reduction in therapeutic outcomes and increases the risk of morbidity/mortality, finding an appropriate pharmacotherapy treatment for this disorder is necessary.ObjectivesThis systematic review contains studies that examine the effects of pharmacological intervention (oral naltrexone (NTX) or injectable extended-release naltrexone (XR-NTX)) on the persons living with HIV and AUDs.MethodsA systematic literature search using three electronic databases including Pubmed Medline, Scopus and the Cochrane Library and Google Scholar was conducted and includes articles published from 1995 to 2019. Records were collected by searching relevant keywords and those that meet the inclusion/exclusion criteria are included.ResultsOverall, in this systematic review, the results of 7 relevant studies including pilot and randomized controlled/clinical trials were summarized and reviewed. Among selected records 2 of these assessed the efficacy of NTX and 5 tested the XR-NTX effectiveness in treating AUDs among persons living with HIV (PLH). In summary, with some expectations, NTX and XR-NTX administration in persons living with HIV and AUDs led to reduced alcohol use, improved viral suppression, unchanged ART adherence and has no significant adverse events.ConclusionThe findings of this systematic review suggest the beneficial effects and safety of the NTX and XR-NTX for treating AUDs in PLH. Further studies are needed in the future to focus on the treatment of AUDs in people living with HIV.
Highlights
Alcohol use disorders (AUDs) are a costly, common and disabling health condition that is considered as one of the most serious public health problems [1]
The main goal of this research is to provide a systematic review of the current evidence regarding the application of naltrexone for the pharmacotherapy of AUDs in people living with human immunodeficiency virus (HIV)
Among 51 people with HIV/AUD enrolled in the study by Korthuis. et al, 2017, 83% of Extended-release naltrexone (XR-NTX) and 50% of treatment as usual (TAU) pharmacotherapy groups were retained on the treatment within 16 weeks [47]
Summary
Alcohol use disorders (AUDs) are a costly, common and disabling health condition that is considered as one of the most serious public health problems [1]. It has been reported that alcohol use is associated with an increase in the risk of chronic illnesses such as cardiovascular disease and cancer in people living with HIV [18,19,20,21,22]. Alcohol use among people living with HIV affects negatively on their adherence and engagement to the HIV treatment, treatment outcomes and mortality risk [7, 23,24,25]. Because alcohol use disorders (AUDs) in patients living with HIV/AIDS are associated with a reduction in therapeutic outcomes and increases the risk of morbidity/mortality, finding an appropriate pharmacotherapy treatment for this disorder is necessary
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
